Head and Neck TumorsHead and Neck TumorsОпухоли головы и шеи2222-14682411-4634Publishing House ABV Press111110.17650/2222-1468-2025-15-3-124-130CLINICAL CASEКЛИНИЧЕСКИЙ СЛУЧАЙmTOR inhibitor as off-label option in treatment of progressive refractory nasopharyngeal carcinomaВозможности персонализированного подхода в лечении распространенного рецидивирующего рака носоглоткиhttps://orcid.org/0000-0002-0918-3857MudunovA. M.МудуновА. М.
Russian Federation

111 1st Uspenskoe Shosse, Lapino, Moscow  Region 143081

Bld. 2, 8 Trubetskaya St., Moscow 11999

143081 Московская обл., д. Лапино, 1-е Успенское шоссе, 111

119991 Москва, ул. Трубецкая, 8, стр. 2

https://orcid.org/0000-0001-9372-3328KhabazovA. M.ХабазоваА. М.
Russian Federation

66 Sevastopolsky Prospekt, 116152 Moscow

116152 Москва, Севастопольский пр-кт, 66

https://orcid.org/0000-0003-4546-0011PakM. B.ПакМ. Б.
Russian Federation

Maxim Bokmanovich Pak 

66 Sevastopolsky Prospekt, 116152 Moscow

Максим Бокманович Пак 

116152 Москва, Севастопольский пр-кт, 66

mbpak@yandex.ruhttps://orcid.org/0000-0001-8727-6111BerelavichusS. V.БерелавичусС. В.
Russian Federation

66 Sevastopolsky Prospekt, 116152 Moscow

116152 Москва, Севастопольский пр-кт, 66

https://orcid.org/0000-0001-7690-731XChenH.ЧэньХ.
China

8 South Gongren Gymnasium Road, Chaoyang District, Beijing 100006

100006 Пекин, район Чаоян, South Gongren Gymnasium Road, 8

Clinical Hospital “Lapino” of the “Mother and Child” Group of companiesКлинический госпиталь «Лапино» группы компаний «Мать и дитя»Sechenov University, Ministry of Health of RussiaФГАОУ ВО Первый Московский государственный медицинский университет им. И. М. Сеченова Минздрава России (Сеченовский Университет)Specialized Medical Center of the Bank of RussiaМногопрофильный медицинский центр Банка РоссииBeijing Chao-Yang hospital, Capital Medical UniversityПекинская больница Чао-Ян, Столичный медицинский университет031120251531241300311202503112025Copyright ©; 2025, Mudunov A.M., Khabazov A.M., Pak M.B., Berelavichus S.V., Chen H.Copyright ©; 2025, Мудунов А.М., Хабазова А.М., Пак М.Б., Берелавичус С.В., Чэнь Х.2025Mudunov A.M., Khabazov A.M., Pak M.B., Berelavichus S.V., Chen H.Мудунов А.М., Хабазова А.М., Пак М.Б., Берелавичус С.В., Чэнь Х.https://creativecommons.org/licenses/by/4.0https://ogsh.abvpress.ru/jour/article/view/1111

Nasopharyngeal carcinoma (NpC) is a malignant tumor developing from the non-keratinizing epithelium of the nasopharynx. In 2022, more that 530,000 new NpC cases were registered worldwide. The rate of NpC in the Russian federation reaches 0.3 % among all malignancies and up to 2 % of head and neck cancers. The 5-year overall survival rate varies from 90 % in patients with stage I NpC to 40 % in those with stage Iv NpC. Over 40 % of newly diagnosed NpC patients already have stage Iv disease.

In this article, we report a case of successful treatment of a patient with locally advanced recurrent nasopharyngeal carcinoma.

Рак носоглотки (назофарингеальная карцинома) – злокачественная опухоль, развивающаяся из неороговевающего эпителия носоглотки. В 2022 г. в мире зафиксировано более 530 тыс. новых случаев данной патологии. В РФ рак носоглотки составляет 0,3 % всех злокачественных новообразований и до 2 % всех злокачественных опухолей головы и шеи. пятилетняя общая выживаемость при заболевании I стадии составляет 90 %, Iv – 40 %. более чем у 40 % пациентов рак носоглотки диагностируют на Iv стадии.

В статье представлен клинический случай успешного лечения пациентки с распространенным рецидивирующим раком носоглотки.

nasopharyngeal cancernasopharyngeal carcinomaomprehensive genomic profilingextensive molecular testingAKT1molecular diagnostics of nasopharyngeal cancertargeted therapyрак носоглоткиназофарингеальная карциномакомплексное геномное профилированиерасширенно агностика рака носоглоткитаргетная терапияEncyclopedia of clinical Oncology: basic tools and methods for the diagnosis and treatment of malignant neoplasms. Ed. by M.I. Davydov. Moscow: RADAR-2004, 2004. 1456 p. (In Russ.).Энциклопедия клинической онкологии: основные средства и методы диагностики и лечения злокачественных новообразований. Под ред. М.И. Давыдова. М: РЛС-2004, 2004. 1456 с.Yang Y., Qu S., Li J. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology 2021;22(8):1162–74. DOI: 10.1016/S1470-2045(21)00302-8Yang Y., Qu S., Li J. et al. Camrelizumab versus placebo in combination with gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (CAPTAIN-1st): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology 2021;22(8):1162–74. DOI: 10.1016/S1470-2045(21)00302-8Al-Anazi A., Alanazi B., Alshanbari H.M. et al. Increased prevalence of EBV infection in nasopharyngeal carcinoma patients: a six-year cross-sectional study. Cancers (Basel) 2023;15(3):643. DOI: 10.3390/cancers15030643Zhang J., Fang W., Qin T. et al. Co-expression of PD-1 and PD-L1 predicts poor outcome in nasopharyngeal carcinoma. Med Oncol 2015;32(3):86. DOI: 10.1155/2022/8537966Blanchard P., Lee A., Marguet S. et al. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol 2015;16(6):645–55. DOI: 10.1016/S1470-2045(15)70126-9Zhang Y., Li W.F., Liu X. et al. Nomogram to predict the benefit of additional induction chemotherapy to concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: analysis of a multicenter, phase III randomized trial. Radiother Oncol 2018;129(1):18–22. DOI: 10.1016/j.radonc.2017.12.002Ribassin-Majed L., Marguet S., Lee A.W. et al. What is the best treatment of locally advanced nasopharyngeal carcinoma? An individual patient data network meta-analysis. J Clin Oncol 2017;35(5):498–505. DOI: 10.1200/JCO.2016.67.4119Chua D.T., Wei W.I., Sham J.S. et al. Treatment outcome for synchronous locoregional failures of nasopharyngeal carcinoma. Head Neck 2003;25(7):585–94. DOI: 10.1002/hed.10242Toumi N., Ennouri S., Charfeddine I. et al. Local and lymph node relapse of nasopharyngeal carcinoma: a single-center experience. Ear Nose Throat J 2020;100(Suppl 5):795S–800S. DOI: 10.1177/0145561320908955Poh S.S., Soong Y.L., Sommat K. et al. Retreatment in locally recurrent nasopharyngeal carcinoma: current status and perspectives. Cancer Commun (Lond) 2021;4(5):361–70. DOI: 10.1002/cac2.12159Bolotina L.V., Vladimirova L.Yu., Dengina N.V. et al. Tumors of the head and neck. Zlokachestvennye opukholi = Malignant Tumors 2024;14(3s2):160–82. (In Russ.). DOI: 10.18027/2224-5057-2024-14-3s2-1.1-09Болотина Л В., Владимирова Л.Ю., Деньгина Н.В. и др. Опухоли головы и шеи. Злокачественные опухоли 2024;14(3s2): 160–82. DOI: 10.18027/2224-5057-2024-14-3s2-1.1-09Shi S., Li B., Zhou P. et al. Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer. Cancer Med 2024;13(14):e7359. DOI: 10.1002/cam4.7359Zhou Z., Li P. et al. Mutational landscape of nasopharyngeal carcinoma based on targeted next-generation sequencing: implications for predicting clinical outcomes. Mol Med 2022;28(1):55. DOI: 10.1186/s10020-022-00479-4Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012;487(7407):330–7. DOI: 10.1038/nature11252Zehir A., Benayed R., Shah R.H. et al. Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients. Nat Med 2017;23(6):703–13. DOI: 10.1038/nm.4333Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129Cancer Genome Atlas Network. Comprehensive genomic characterization of head and neck squamous cell carcinomas. Nature 2015;517(7536):576–82. DOI: 10.1038/nature14129Cheaib B., Auguste A., Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer 2015;34(1):4–16. DOI: 10.5732/cjc.014.10289Cheaib B., Auguste A., Leary A. The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges. Chin J Cancer 2015;34(1):4–16. DOI: 10.5732/cjc.014.10289Vivanco I., Sawyers C.L. The phosphatidylinositol 3-kinase AKT pathway in human cancer. Nat Rev Cancer 2002;2(7):489–501. DOI: 10.1038/nrc839Bessiere L., Todeschini A.-L. et al. A Hot-spot of In-frame ̀ duplications activates the oncoprotein AKT1 in juvenile granulosa cell tumors. eBioMedicine 2015;2(5):421–31. DOI: 10.1016/j.ebiom.2015.03.002Auguste A., Bessiere L., Auguste A. et al. Molecular analyses ̀ of juvenile granulosa cell tumors bearing AKT1 mutations provide insights into tumor biology and therapeutic leads. Hum Mol Genet 2015;24(23):6687–98. DOI: 10.1093/hmg/ddv373Chang M.T., Bhattarai T.S., Schram A.M. et al. Accelerating discovery of functional mutant alleles in cancer. Cancer Discov 2018;8(2):174–83. DOI: 10.1158/2159-8290.CD-17-0321Yeh Y.-C., Ho H.-L., Wu Y.C. et al. AKT1 internal tandem duplications and point mutations are the genetic hallmarks of sclerosing pneumocytoma. Mod Pathol 2020;33(3):391–403. DOI: 10.1038/s41379-019-0357-yParikh C., Janakiraman V., Wu W.I. et al. Disruption of PH-kinase domain interactions leads to oncogenic activation of AKT in human cancers. Proc Natl Acad Sci USA 2012;109(47):19368–73. DOI: 10.1073/pnas.1204384109Calleja V., Laguerre M., Parker P.J., Larijani B. et al. Role of a novel PH-kinase domain interface in PKB/Akt regulation: structural mechanism for allosteric inhibition. PLoS Biol 2009;7(1):e17. DOI: 10.1371/journal.pbio.1000017Smyth L.M., Tamura K., Oliveira M. et al. Capivasertib, an AKT kinase inhibitor, as monotherapy or in combination with fulvestrant in patients with AKT1E17K-mutant, ER-positive metastatic breast cancer. Clin Cancer Res 2020;26(15):3947–57. DOI: 10.1158/1078-0432.CCR-19-3953Kalinsky K., Zihan W., Kalinsky K. et al. Ipatasertib in patients with tumors with AKT mutations: results from the NCI-MATCH ECOG-ACRIn trial (EAY131) sub-protocol Z1K. Clin Cancer Res 2025. DOI: 10.1158/1078-0432.CCR-24-3431Yu Z., Wei W., Liu H. et al. Efficient everolimus treatment for metastatic castration resistant prostate cancer with akt1 mutation: a case report. Onco Targets Ther 2021;14:5423–8. DOI: 10.2147/OTT.S334205Yu Z., Wei W., Liu H. et al. Efficient everolimus treatment for metastatic castration resistant prostate cancer with akt1 mutation: a case report. Onco Targets Ther 2021;14:5423–8. DOI: 10.2147/OTT.S334205Giannakis M., Mu X.J., Shukla S.A. et al. Genomic correlates of immune-cell infiltrates in colorectal carcinoma. Cell Rep 2016;15(4):857–65. DOI: 10.1016/j.celrep.2016.03.075Tredan O., Treilleux I., Wang Q. et al. Predicting everolimus ́ treatment efficacy in patients with advanced endometrial carcinoma: a GINECO group study. Target Oncol 2013;8(4):243–51. DOI: 10.1007/s11523-012-0242-9Schneider T.C., de Wit D., Links T.P. et al. Everolimus in patients with advanced follicular-derived thyroid cancer: results of a phase II clinical trial. J Clin Endocrinol Metab 2017;102(2):698–707. DOI: 10.1210/jc.2016-2525Bryce A.H., Egan J.B., Borad M.J. et al. Experience with precision genomics and tumor board, indicates frequent target identification, but barriers to delivery. Oncotarget 2017;8(16):27145–54. DOI: 10.18632/oncotarget.16057